Showing 3911-3920 of 6038 results for "".
- gloProfessional Official Uniform Sponsor of Women's USA Field Hockey Teamhttps://practicaldermatology.com/news/20120719-gloprofessional_official_uniform_sponsor_of_womens_usa_field_hockey_team/2459769/The USA field hockey team announced a premier partnership with gloProfessional. The multi-year agreement will feature glo on the front of the Women's National Team jersey and podium suits and represents the first ever corporate advertiser
- Wellness Center USA Inc. Signs Agreement to Acquire Psoria-Shield Inc.https://practicaldermatology.com/news/20120626-wellness_center_usa_inc_signs_agreement_to_acquire_psoria-shield_inc/2459782/Wellness Center USA Inc.(OTCQB/OTCBB: WCUI), a healthcare and nutraceutical company, signed a share exchange agreement to acquire Psoria-Shield Inc. (PSI), a developer and manufacturer of UV p
- Stiefel, a GSK Company, Acquires Worldwide Rights to Toctino (alitretinoin)https://practicaldermatology.com/news/20120612-stiefel_a_gsk_company_acquires_worldwide_rights_to_toctino_alitretinoin/2459784/Stiefel, a GSK company, has entered into a worldwide agreement to acquire Toctino (alitretinoin) from Basilea Pharmaceutica Ltd. A once-daily oral retinoid, Toctino is in Phase 3 trials in the US, where it has not yet received FDA approval. Globally, it is the only prescription medicine specifically
- Suneva to Acquire Worldwide Rights to Refissa(R)https://practicaldermatology.com/news/20120604-suneva_to_acquire_worldwide_rights_to_refissar/2459789/Suneva Medical , a privately-held aesthetics company, will acquire worldwide rights to Refissa® and its marketed generic equivalent from Spear Pharmaceuticals. The portfolio contains the only tretinoin creams with
- New Retinoid Foam Wins FDA Approvalhttps://practicaldermatology.com/news/20120514-new_retinoid_foam_wins_fda_approval/2459805/The FDA has approved Fabior (tazarotene) Foam, 0.1%, for the treatment of acne vulgaris in patients 12 years and older. The approval was based on two multi-center, randomized, double-blind, vehicle-controlled pivotal Phase 3 studies, in which a total of 1,485 patients with moderate-to-severe acne vu
- Mylan, Impax Win Ruling in Doryx Generics Patent Casehttps://practicaldermatology.com/news/20120502-mylan_impax_win_ruling_in_doryx_generics_patent_case/2459810/Mylan Inc. (MYL) said it began selling a generic version of the antibiotic Doryx today after a judge ruled it didn't infringe a patent held by Warner Chilcott (WCRX) Plc.
- Warning for Blood Clot Risk Added to Drospirenone OCPshttps://practicaldermatology.com/news/20120411-warning_for_blood_clot_risk_added_to_drospirenone_ocps/2459827/The U.S. Food and Drug Administration (FDA) has completed its review of recent observational (epidemiologic) studies regarding the risk of blood clots in women taking drospirenone-containing birth control pills. Drospirenone is a synthetic version of the female hormone, progesterone, also referred t
- Merz Clarifies Status of Xeomin, Appoints William (Bill) Humphries CEOhttps://practicaldermatology.com/news/20120314-merz_clarifies_status_of_xeomin_appoints_new_ceo/2459845/Following a hearing in US District Court yesterday, Merz, Inc. is clarifying the availability of Xeomin and has appointed William (Bill) D. Humphries as CEO of Merz Inc., effective March 15. Merz Pharmaceuticals, LLC will continue to sell Xeomin fo
- Delicious Living magazine recognizes Wildly Natural Seaweed Body Creamhttps://practicaldermatology.com/news/20120229-delicious_living_magazine_recognizes_wildly_natural_seaweed_body_cream/2459862/The Delicious Living 2012 Beauty & Body Award for “Best New Product” went to The Seaweed Bath Co.'s Wildly Natural SeaweedTM Body Cream, the company announced. Delicious Living chose winners based on the products' efficacy without sacrificing purity, innovation and their dedication to raising standa
- What New Secukinumab Data Mean for HS Patients: A Q&A with Dr. April Armstronghttps://practicaldermatology.com/news/what-new-secukinumab-data-mean-for-hs-patients-a-qa-with-dr-april-armstrong/2486412/In the following Q&A, Dr. April Armstrong, professor and chief of dermatology at UCLA and a study coauthor, talks with Practical Dermatology about the importance of new secukinumab data for patients with hidradenitis suppurativa (HS). Speaking on UCB's recently announced top